Ajinomoto Co., Inc. and Forge Biologics announced they have entered into a definitive agreement by which Ajinomoto Co., will acquire Forge, a manufacturer of genetic medicines, in an all-cash deal for $620 million. 

Forge is a viral vector and plasmid contract development and manufacturing organization (CDMO) and clinical-stage therapeutics company, enabling access to potentially life-changing gene therapies by bringing them from concept to reality. All development and manufacturing is done at the Hearth, Forge’s 200,000-sq.-ft. custom-designed cGMP facility in Columbus, Ohio, where the business has over 300 employees. 

“Forge has had remarkable growth since our founding in 2020, and we’re excited to join Ajinomoto Co., to continue to expand our global business of helping innovators manufacture much needed genetic medicines,” says Timothy J. Miller, Ph.D., CEO, President, and Co-founder of Forge. “Our teams share a commitment to investing in innovation that helps our clients succeed in delivering therapies to patients in need. We set out to build a company with a mission to enable access to life-changing discoveries, and this transaction will support us in advancing that mission into our next global stage of development to expand our capabilities and platform for the benefit of our clients and their patients.” 

“Forge’s unparalleled expertise in gene therapy development and manufacturing will be a transformative addition to our core growth area of Healthcare as part of our ASV Initiatives 2030 Roadmap. Forge brings to Ajinomoto an entirely new capability that will vitally enhance our Bio-Pharma Services business and help create new value through innovative solutions for communities and society,” says Yasuyuki Otake, Corporate Executive, General Manager of Bio-Pharma Services Department of Ajinomoto Co. “We look forward to working with Forge’s incredibly talented team and state-of-the-art specialized manufacturing facility to expand our platform technologies aimed to help realize Ajinomoto’s ‘Purpose’ of contributing to the well-being of all human beings, our society, and our planet.”

“This is a tremendous step to drive Forge’s next phase of growth that will maximize the impact they have on their mission for clients and patients,” says Chris Garabedian, Chairman and CEO of Xontogeny and Chairman of Forge’s Board of Directors. “This acquisition in the current biotech market is a remarkable testament to the technical advancements, world-class facility, and experienced capable leadership at Forge.”